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Background
Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resembles 
a diffuse large B-cell lymphoma, and it is a subtype of primary central nervous system 
lymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. 
We retrospectively analyzed IOL patient data to identify treatment patterns and survival 
rates in Korea.
Methods
Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinical 
data collected from medical records included Ann Arbor stage, International Prognostic 
Index, performance status, date of diagnosis, treatment modality and response, date of 
relapse, and date of last follow-up.
Results
Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 
at multiple centers in Korea, were included in the analysis. Four patients were diagnosed 
with IOL alone, not involving the CNS. Two patients with isolated IOL later developed 
PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Five 
patients had simultaneous onset in the eye and CNS. Twelve patients were treated by intra-
vitreal injection of methotrexate for IOL. The median progression-free survival (PFS) for 
patients was 19.7 months (95% CI, 8.7‒30.7 mo). The estimated 3-year overall survival 
(OS) for all patients was 75.1%.
Conclusion
Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL pa-
tients showed favorable PFS and OS. These patients would require long-term follow-up 
to identify relapse and adverse effects of radiotherapy or intraocular chemotherapy. 
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INTRODUCTION
Intraocular lymphoma (IOL) is a rare malignant lymphoma 
that most closely resembles a diffuse large B-cell lymphoma, 
and it is a subtype of primary central nervous system lympho-
ma (PCNSL) [1, 2]. IOL constitutes ＜1% of intraocular tu-
mors and 1% of non-Hodgkin’s lymphoma [3]. IOL is a 
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heterogeneous group of lymphomas that can be located in 
different tissues within the eyes, including the retina, uvea, 
and optic nerve. According to the WHO classification, IOL 
can be classified as vitreoretinal lymphoma (VRL) or uveal 
lymphoma. VRL may involve the retina, whereas uveal lym-
phoma may be further sub-classified as choroidal, ciliary 
body, or iridal. Most IOL cases are primary VRL rather 
than uveal lymphoma. 
IOL was first described in 1951 as “malignant lymphoma 
of the uveal tract” [4]. Since then, there have been several 
reports of IOL. Blurred vision, reduced vision, and floaters 
are the common initial subjective symptoms [5]. Among 
IOL patients, the percentage of cases that involve the CNS 
is 60–80% [5]. Manifested symptoms of PCNSL are very 
different, depending on the presence of a brain lesion.
IOL is an aggressive lymphoma that requires early diag-
nosis and treatment for a good prognosis [6]. However, a 
uniform method of IOL diagnosis and treatment has not 
yet been established owing to the low incidence. Definitive 
diagnosis of IOL requires histopathologic evidence of malig-
nant lymphoma cells in ocular specimens. However, IOL 
can be misdiagnosed as intraocular inflammation [7]. 
Therefore, several supplementary diagnostic methods are 
currently used to support the diagnosis of IOL, including 
cytokine, molecular, and genetic analyses. Treatment modal-
ities for IOL include intravitreal injection, systemic chemo-
therapy, and radiotherapy, used alone or in an appropriate 
combination. Treatment protocols for IOL have not been 
validated [8].
Recently, IOL has received increasing attention following 
reported reviews of a large number of cases in America 
and Japan [5, 9]. However, there are no large scale studies 
of IOL in Korea [10]. Hence, its clinical manifestation, treat-
ment, and prognosis remain unclear. In this multicenter, 
retrospective study, we reviewed cases of IOL diagnosed 
by cytology. We presented the clinical features associated 
with PCNSL and discussed diagnosis and treatment.
MATERIALS AND METHODS
Twenty patients who were diagnosed with IOL, between 
December 2007 and June 2014 at multiple centers in Korea, 
were included in the analysis. The criteria for case inclusion 
was pathologically confirmed IOL through morphologic 
findings. All suspected IOL patients were confirmed by 
cytology. Included patients had (1) primary IOL only, (2) 
PCNSL and IOL simultaneously, or (3) PCNSL without ocular 
involvement at diagnosis that subsequently arose. Institutio-
nal review approval was obtained for the retrospective study 
(DAUH-IRB-13-161).
All primary IOL patients were examined by cranial mag-
netic resonance imaging (MRI) and/or computed tomography 
(CT) to detect CNS lesions during the follow-up period. 
Clinical data collected from patient records included patient 
demographics, International Prognostic Index (IPI), per-
formance status, date of diagnosis, method of treatment, 
treatment response, date of relapse, and date of last follow-up. 
Treatment differed between IOL and PCNSL patients, and 
the various treatment methods were reported.
Overall survival (OS) and progression-free survival (PFS) 
were estimated using the Kaplan-Meier product-limit 
method. OS was measured from the date of treatment to 
the date of death or the last follow-up visit. PFS was calculated 
from the date of diagnosis of IOL to the first documented 
progression, death, or the last follow-up visit. Survival rates 
were compared for statistical differences by using log-rank 
analysis. Data were analyzed using IBM SPSS Statistics ver-
sion 20.0. 
RESULTS
Patient characteristics
The clinical characteristics of the patients are shown in 
Table 1. Thirteen men and 7 women were included in this 
study. The median patient age was 59 years (range, 34–76 
yr). None of the patients had B symptoms. According to 
the IPI, 13 cases were classified as low-risk, 6 cases were 
classified as low-intermediate or high-intermediate risk, and 
1 case was classified as high risk. No patient had lymph 
node metastasis, and all patients had tumors ＜10 cm. The 
location involving brain lesions differed, with the frontal 
lobe being the most common site. One case outside the 
CNS involved the muscles. All patients had a cytologic diag-
nosis of lymphoma. All cases were VRL. Eighteen cases were 
diffuse large B-cell lymphoma, whereas the other 2 cases 
were unable to be classified because of the paucity of diag-
nostic samples. 
Eleven patients developed ocular lesions first. Among 
these, 4 patients were diagnosed with IOL alone, not involv-
ing the CNS. Two of these patients later developed CNS 
lesions. Five patients had simultaneous onset in the eye and 
CNS. Nine patients developed CNS lesions before the onset 
of ocular lymphoma. The intervals between the onset of 
the primary ocular lesion and the secondary CNS lesion 
were 7 months and 20 months in the 2 patients, whereas 
the median interval between the onset of primary CNS lesions 
and secondary ocular lesions was 19 months (range, 5–48 
mo) in 9 patients. In the 20 patients with confirmed IOL, 
a total of 8 vitrectomies were performed.
Intraocular lymphoma treatment
The method of treatment for IOL varied greatly. Twelve 
patients were treated by intravitreal injection of methotrex-
ate (MTX). Among these, 3 patients received combination 
therapy with intraocular radiation or intravenous chemo-
therapy, and 9 patients received intravitreal MTX alone. 
Three patients with concurrent IOL and CNS lymphoma 
lesions were treated only for PCNSL. Two patients received 
orbital radiation. Three patients underwent systemic chemo-
therapy with intravenous CYVE (high-dose cytarabine and 
etoposide), ICE (ifosfamide, carboplatin, etoposide), or high 
dose MTX plus cytarabine.
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Table 1. Clinical characteristics of intraocular lymphoma patients in Korea.
No. Gender/Age
Lymphoma 
site
Brain 
lesion site
Ocular 
treatment
Systemic 
treatment
PFS 
(mo)
OS 
(mo)
Primary IOL
1 M/71 IOL only None IO MTX 0.5 0.5
2 F/59 IOL only None IO MTX 54.4+ 54.4+
3 M/57 IOL only None IO MTX 41.4+ 41.4+
4 M/65 IOL only None IO MTX 51.1+ 51.1+
IOL → CNS
5 F/50 IOL → CNSL None IO MTX+HD MTX+Ara-C 20.3 26.3+
6 F/71 IOL → CNSL None IO MTX OP+MTX 6.7 6.8+
IOL + CNS
7 M/76 IOL, CNSL Frontal lobe IO MTX WBRT 8 8
8 F/54 IOL, CNSL BG, LMS HD MTX+ARA-C HD MTX+Ara-C 25.4 34.3+
9 F/48 IOL, CNSL Diffuse infiltration HD MTX+Ara-C 0.5 1.1
10 M/74 IOL, CNSL Frontal lobe WBRT 5.7+ 5.7+
11 F/74 IOL, CNSL Frontal lobe HD MTX+WBRT 17.8+ 17.8+
CNS → IOL
12 M/48 CNSL → IOL None IV CYVE HD MTX 17.1 19.4+
13 F/34 CNSL → IOL Frontal lobe, Thalamus IO MTX HD MTX+procar+vinc+HSCT 12.5 44.7+
14 M/55 CNSL → IOL Thalamus, Cerebellum IO MTX HD MTX+WBRT 2.6 3.6+
15 M/65 CNSL → IOL unknown IO MTX HD MTX+WBRT 1.6 1.6
16 M/57 CNSL → IOL Thalamus IV ICE HD MTX+IT+WBRT 7.7 22.8
17 M/50 CNSL → IOL Frontal lobe IO MTX+ORT+IV CTx, HD MTX+WBRT 13.1 21.8
18 M/46 CNSL → IOL Thalamus IO MTX+ORT HD MTX+Ara-C+IT+WBRT 19.7 33.4+
19 M/62 CNSL → IOL None ORT HD MTX+Ara-C 0.2+ 0.2+
20 M/57 CNSL → IOL Postero-occipital lobe ORT HD MTX 1.6+ 1.6+
Abbreviations: IOL, intraocular lymphoma; CNSL, central nervous system lymphoma; BG, basal ganglia; LMS, leptomeningeal seeding; IO 
MTX, intraocular methotrexate injection; HD MTX, high dose methotrexate; Ara-C, cytarabine; CYVE, high-dose cytarabine and etoposide; 
ORT, ocular radiotherapy; WBRT, whole brain radiotherapy; IT, intrathecal chemotherapy; procar, procarbazine; vinc, vincristine; HSCT, 
hematopoietic stem cell transplantation.
Fig. 1. Progression-free survival (PFS) and overall survival (OS) curves 
of patients with intraocular lymphoma. The median PFS of a patient was 
19.7 months (95% CI, 8.7–30.7 mo). The estimated 3-year OS of all 
patients was 75.1%.
The method of treatment for PCNSL likewise varied. 
High-dose MTX was administered to most patients. Thirteen 
of 16 total cases involved CNS. Only 3 patients received 
treatment with high-dose MTX alone: 1 patient was treated 
with high-dose MTX combined with whole brain radiation 
therapy, cytarabine, or operation, and the other 2 patients 
received whole brain radiation therapy alone. Among them, 
one patient died after PCNSL was detected.
Survival of patients with intraocular lymphoma
The median PFS for patients was 19.7 months (95% CI, 
8.7–30.7 mo). The estimated 3-year OS of all patients was 
75.1% (Fig. 1). Patients who presented initially with IOL, 
either alone or with simultaneous PCNSL, had a median 
PFS of 25.4 months (95% CI, 18.0–48.3 mo) and a 90% 
3-yr OS rate (Fig. 2). IOL patients who were subsequently 
diagnosed with PCNSL at follow-up had a median PFS of 
12.5 months (95% CI, 6.0–9.0 mo) and a 53.3% 3-year OS 
rate (Fig. 3).
DISCUSSION
In the current study, we reviewed cases of IOL in Korea 
diagnosed by cytology and presented the associated clinical 
features. IOL has a low incidence with very few previous 
reports; hence, we identified only 20 cases. Of the different 
treatments for IOL, intravitreal MTX injection was the most 
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Fig. 2. Survival of primary intraocular lymphoma (IOL) patients, 
including those with primary IOL alone or that simultaneously detected 
with primary central nervous system lymphoma (PCNSL). Patients with 
primary IOL that were subsequently diagnosed with PCNSL had a 
median progression-free survival (PFS) of 25.4 months (95% CI, 18.0–
48.3 mo) and a 3-year overall survival (OS) rate of 90%.
Fig. 3. Survival of patients with primary central nervous system 
lymphoma (PCNSL) that were subsequently diagnosed with intraocular 
lymphoma (IOL) had a median progression-free survival (PFS) of 12.5 
months (95% CI, 6.0–19.0 mo) and a 3-year overall survival (OS) rate 
of 53.3%.
common. Nine PCNSL patients were diagnosed with ocular 
lesions during follow-up, with a median time between diag-
noses of 19 months. 
IOL commonly develops in individuals aged 50 to 60 years 
old, and the ratio of male to female patients is 1.0:1.5 [11]. 
In our study, the median age of IOL patients was 58.7 years, 
similar to the reported statistics, but there were more men 
compared to women. In 1987, Freeman et al. [12] reported 
32 cases (18 ocular and CNS, 7 ocular only, and 7 others) 
in which patients had a 5-year survival rate of ＜30%. In 
a Japanese study by Kimura et al. [5], the 5-year survival 
rate improved to 61.1%. Compared with the two previous 
reports, the higher IOL survival rate in our study may have 
shown due to the improvement in the diagnosis and treat-
ment of lymphoma. In this study, the median PFS of patients 
was 19.7 months (95% CI, 8.7–30.7 mo), and the estimated 
3-year OS of all patients was 75.1%. The good prognosis 
can be explained by the higher proportion of primary IOL 
among the enrolled patients. IOL patients presenting ocular 
symptoms have a relatively good prognosis, whereas the 
patients with PCNSL and later ocular involvement have a 
poor survival prognosis. Primary IOL was present in 4 
patients. The onset of CNS lesions and subsequent onset 
of ocular lesions led to a median PFS of 25.4 months (95% 
CI, 18.0–48.3 mo) and a 90% 3-year OS rate. The other 
11 patients had a median PFS of 12.5 months (95% CI, 
6.0–19.0 mo) and a 53.3% 3-year OS rate. However, there 
was no statistical difference among OS of the two groups 
in our study. 
Two patients with isolated IOL developed PCNSL sub-
sequently and the intervals between their onset of the pri-
mary ocular lesion and the secondary CNS lesion were 20 
months and 7 months. Whereas the median interval between 
the onset of primary CNS lesions and secondary ocular lesion 
was 19 months (range, 5–48 mo) for 9 patients. Kimura et 
al. [5] reported that the interval between the onset of primary 
ocular lesions and subsequent onset of CNS lesions was sig-
nificantly longer than that between the onset of primary 
CNS lesions and subsequent onset of ocular lesions. This 
suggests that primary IOL tends to be relatively slow pro-
gressing, and regular follow-up, including appropriate neuro-
imaging, is important for these patients after treatment since 
they carry a risk for recurrence for several years after the 
disease has been dormant. Compared with the Japanese study, 
the onset pattern of IOL observed here was quite different. 
The patients with the most common onset pattern of IOL 
(45%) exhibited subsequent manifestation of PCNSL, but 
the Japanese study was mostly consisted of primary IOL 
(82.5%). The method of IOL diagnosis could be the main 
reason for this difference. In our study, all cases were con-
firmed by cytology and not cytokine analysis. Cytokine anal-
ysis (intravitreal IL-10/IL-6 ratio ＞1.0) and gene rearrange-
ment of the vitreous specimens were used in the Japanese 
data. Positive rates of IOL diagnosis by cytokine analysis 
(91.7%) and gene rearrangement (80.6%) are much higher 
compared to those on cytological examination (44.5%) [5]. 
Therefore, more early detection could be possible. Vitrectomy 
was first performed for diagnosis of IOL in 1975 [13]. In 
the past 3 decades, diagnostic vitrectomies have become the 
accepted and preferred procedure for diagnosing IOL, thus 
replacing brain biopsy. The paucity of lymphoma cells in 
the vitreous make adequate tissue harvest and preservation 
for cytologic analysis a challenge [14]. Fine needle aspiration 
of the vitreous also yields cytologic vitreous specimens. 
Cytological examination of vitreous biopsy specimens is re-
ported to achieve a very high positive rate [15]. However, 
the false-negative rate is about 50%. This could be due to 
corticosteroids administered because of misdiagnosed in-
flammation or the effects of whole brain irradiation treat-
ment for PCNSL [5]. Recently, supplementary diagnostic 
tools, including those to detect the IL-10/IL-6 ratio and IgH 
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gene rearrangement, were developed. Cytokine analysis of 
the vitreous specimens is a supplementary diagnostic method 
and an intravitreal IL-10/IL-6 ratio ＞1.0 is suggested as 
the diagnostic criteria for lymphoma. The sensitivity based 
on this criterion is reported as 75% [16], whereas that of 
detecting IgH gene arrangements is 64% [17]. There is a 
need for supplementary diagnostic methods in future clinical 
practice.
Until now, treatment guidelines had not been established. 
The ultimate goal of treatment is to eradicate the IOL cells, 
eliminating the potential reservoir of untreated disease that 
could cause recurrence or CNS extension [18]. In our study, 
intravitreal MTX injection was the most common treatment 
for IOL, as it was used in 12 patients. Four patients received 
radiation treatment. Radiation to the eye is used for treatment 
of IOL and induces an ocular remission. However, radiation 
therapy has limitations. Hoffman et al. [11] reported that 
five out of nine patients who received radiation therapy 
had recurrence, and orbital irradiation caused ocular tox-
icities, including cataract, radiation retinopathy, optic neuro-
pathy, and dry eyes. In recent years, a protocol for treating 
IOL with intravitreal injections of MTX was developed at 
the Oregon Health & Science University [19]. This treatment 
effectively induced clinical remission of IOL with acceptable 
morbidity. Treatment with intravitreal MTX injections re-
sulted in some complications, such as keratopathy, accel-
eration of existing cataract, and neovascularization of the 
iris [20].
This study collected cases of IOL from multi-centers for 
about 7 years in Korea. Because it was not a cohort study, 
we cannot know the actual incidence of IOL. This is one 
of the major limitations of the study. The other limitations 
of our study are its retrospective nature, the small sample 
size, and the different treatment methods. IOL is a very 
rare lymphoma. Hence our study enrolled only 20 patients. 
Blurred vision and ataxia were the most common ocular 
and extra-ocular symptoms that prompted patients to seek 
medical examination in the Japanese data [5], but we were 
unable to examine information about sign and symptom 
because of the lack of medical data. 
In addition, the follow-up period was too short. If the 
follow-up period was sufficient, it would have been possible 
to identify primary IOL patients with subsequent CNS 
lesions. In addition, we enrolled a higher proportion of pri-
mary IOL cases, as compared to earlier studies. More case 
studies and long follow-up periods are needed to determine 
treatment effects and prognoses. 
IOL remains a clinical diagnostic challenge. Patients with 
suspected IOL should undergo histocytologic examination 
of vitreal fluid or vitrectomy before steroid therapy. Once 
IOL is diagnosed, all patients are required to be screened 
in collaboration with an oncologist for subtle neurological 
symptoms and signs, and neuroimaging is performed to detect 
any evidence of CNS involvement. An established method 
of IOL treatment is needed. Moreover, these patients require 
long-term follow-up to rule out disease recurrence or adverse 
effects of radiotherapy or intraocular chemotherapy. 
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